The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Glucagon prescriptions for severe hypoglycemia rose in Medicaid beneficiaries with the introduction of newer products but likely met only a fraction of the high-risk population’s needs.

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.